Ranjits Bindra News Today

Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.

A nanoparticle-based treatment developed by researchers at Yale and the University of Connecticut is aimed at fighting glioblastoma.

A nanoparticle-based treatment developed by researchers at Yale and the University of Connecticut is aimed at fighting glioblastoma.

 E-Mail IMAGE: Identification of potential regulators of the selective alt-NHEJ inhibition of mibefradil. (A) A schematic representation of the Relative Assessment of DNA Repair (RADAR) plot showing the significance of the different... view more  Credit: Correspondence to - Yulia V. Surovtseva - yulia.surovtseva@yale.edu and Ranjit S. Bindra - ranjit.bindra@yale.edu Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore" which reported that ...